Find disease awareness content and relevant supporting materials
The cost of persistent asthma in Europe: an international population-based study in adults.
Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines].
Burden and cost of neurological diseases: a European North-South comparison.
Objectives: To address the relationship between years lived with a disability (YLDs), prevalence and cost of neurological diseases, and to test whether there is a European North–South gradient for national health expenditure, disability, costs and prevalence of neurological diseases.
Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation.
Background: Fibrinogen repletion in patients with acquired bleeding disorders can be accomplished by transfusing cryoprecipitate AHF (cryo) or fibrinogen concentrate (FC); thus, we undertook an economic evaluation from...
Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.
Background: The aim of this study was to determine the economic burden and health-related quality of life (HRQOL) of patients with Spinal Muscular Atrophy (SMA) and their caregivers in Spain.
Migraine in childhood: an organic, biobehavioral, or psychosomatic disorder?
Migraine is one of the most frequent complaints in children and adolescents and it can have a significant impact on quality of life. There are several factors underlying the onset and the maintenance of this disorder and there...
The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Objective: Inflammatory bowel disease [IBD] entails a high economic burden to society. We aimed to estimate the current and future impact of the introduction of biosimilars for infliximab on IBD-related health care costs.
Vaxart announces publication of a peer-reviewed journal article showing the potential clinical and economic value of a norovirus vaccine.
Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, including a Phase II ready norovirus program, announced health care economic findings published in the American Journal of Preventative Medicine.